<DOC>
	<DOC>NCT00268632</DOC>
	<brief_summary>The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.</brief_summary>
	<brief_title>IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>Ambulatory women, Caucasian, Oriental or Multiracial not previously diagnosed for osteoporosis. Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis and having used oral or parenteral glucocorticoids (&gt;= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>